ReviewFrontiers in pharmacology2025
Exploring the pathogenesis of acute lung injury and its treatment through Traditional Chinese Medicine: a state-of-the-art review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cordycepin Alleviates Acute Lung Injury by Targeting TAK1 to Inhibit MAPK and NF-κB Signaling Pathways.Biomolecules · 2026Article
- Salvianolic Acid B Inhibits Ferroptosis in Acute Lung Injury: Network Analysis and Experimental Validation.Journal of cellular and molecular medicine · 2026Article
- Yangxin Tongluo Decoction Protects Against Sepsis-Associated Cardiac Dysfunction Through Regulating Nrf2 Pathway.Mediators of inflammation · 2026Article
- The Role of Histone Modifications in Acute Lung Injury: Molecular Mechanisms and Potential of Traditional Chinese Medicine Treatment.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Lung Injury (ALI) is a severe and progressive condition characterized by hypoxic respiratory failure, often triggered by multiple contributing factors. It is associated with high morbidity and mortality rates and can advance to Acute Respiratory Distress Syndrome (ARDS) in severe cases. The pathogenesis of ALI involves a complex interplay of pathological mechanisms, including immune-inflammatory responses, disruption of the alveolar-capillary barrier, damage to mesenchymal stem cell organelles, metabolic dysregulation, ferroptosis, and alterations in gut microbiota. From the perspective of Traditional Chinese Medicine (TCM), the development of ALI is primarily attributed to the invasion of toxic pathogens, which result in lung dysfunction. TCM treatment strategies, which emphasize heat-clearing, detoxification, promoting blood circulation, and resolving stasis, have demonstrated promising clinical efficacy. This paper provides a comprehensive analysis of the pathogenesis of ALI and explores the therapeutic mechanisms of TCM compounds and bioactive monomers with potential therapeutic benefits. The goal is to establish a solid theoretical foundation for the clinical application of TCM in ALI treatment and to further validate its scientific rationale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.